This site is intended for healthcare professionals
News

Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE phase IIIb trial.- AstraZeneca.

Read time: 1 mins
Last updated:31th Oct 2020
Published:31th Oct 2020
Condition: Asthma (Eosinophilic)
Type: drug
Register free for full access to medthority.com